Paradigm Biopharmaceuticals Limited Stock Price

At a current market capitalisation of approximately A$150 million , Paradigm Biopharmaceuticals appears materially undervalued when compared to peers advancing osteoarthritis (OA) disease modifying therapies, particularly Kolon TissueGene , whose valuation translates to ~A$55 per share at today’s exchange rates. Kolon’s lead asset, TG‑C , is a gene modified, allogeneic cell therapy combining irradiated chondrocytes with HEK293 cells overexpressing TGF‑β1, and is currently in a global Phase 3 trial for knee OA.Read more

Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.Read more